In last trading session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) saw 0.61 million shares changing hands with its beta currently measuring -1.44. Company’s recent per share price level of $13.77 trading at -$0.29 or -2.06% at ring of the bell on the day assigns it a market valuation of $1.20B. That closing price of DAWN’s stock is at a discount of -29.63% from its 52-week high price of $17.85 and is indicating a premium of 29.77% from its 52-week low price of $9.67. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.74 million shares which gives us an average trading volume of 630.01K if we extend that period to 3-months.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Upright in the red during last session for losing -2.06%, in the last five days DAWN remained trading in the red while hitting it’s week-highest on Thursday, 04/11/24 when the stock touched $13.77 price level, adding 7.21% to its value on the day. Day One Biopharmaceuticals Inc’s shares saw a change of -5.68% in year-to-date performance and have moved -5.49% in past 5-day. Day One Biopharmaceuticals Inc (NASDAQ:DAWN) showed a performance of -7.52% in past 30-days. Number of shares sold short was 8.98 million shares which calculate 10.21 days to cover the short interests.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
Statistics highlight that Day One Biopharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 18.71% of value to its shares in past 6 months, showing an annual growth rate of -12.24% while that of industry is 13.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -11.90% in the current quarter and calculating -9.80% decrease in the next quarter.
And 6 analysts are in estimates of company making revenue of $570k in the next quarter that will end on Jun 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -84.59% during past 5 years.
DAWN Dividends
Day One Biopharmaceuticals Inc is more likely to be releasing its next quarterly report in May and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders
Insiders are in possession of 19.70% of company’s total shares while institution are holding 89.21 percent of that, with stock having share float percentage of 111.10%. Investors also watch the number of corporate investors in a company very closely, which is 89.21% institutions for Day One Biopharmaceuticals Inc that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at DAWN for having 7.81 million shares of worth $93.25 million. And as of Jun 29, 2023, it was holding 8.98% of the company’s outstanding shares.
The second largest institutional holder is Atlas Venture Life Science Advisors, LLC, which was holding about 7.61 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 8.75% of outstanding shares, having a total worth of $90.84 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 2.45 million shares of worth $33.07 million or 2.82% of the total outstanding shares. The later fund manager was in possession of 1.86 million shares on Jun 29, 2023, making its stake of worth around $22.17 million in the company or a holder of 2.14% of company’s stock.
